Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshio Ogino

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|March 8, 2005
Pituitary abscess in a patient with painless thyroiditisAkira Matsuno, Yoshio Ogino, Haruko Katayama, et al.
Expert Opinion on Therapeutic Patents|September 12, 2009
Modulation of neuropeptide Y receptors for the treatment of obesityNagaaki Sato, Yoshio Ogino, Satoshi Mashiko, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 15, 2011
[Trigger point therapy for myofascial pain in cancer patients (first report)-analysis results of special use-results surveillance by Neovitacain® injection-]Asami Yamaguchi, Yoshio Ogino, Chie Iwakoshi, et al.
Case Reports in Obstetrics and Gynecology|September 4, 2014
An Unusual Case of Fulminant Type 1 Diabetes during the Second Trimester of PregnancyTomohiro Okuda, Sadao Yamashita, Yoshio Ogino, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 17, 2012
[Trigger point therapy for myofascial pain in cancer patients (second report) analysis results of special use-results surveillance by neovitacain® injection]Asami Yamaguchi, Yoshio Ogino, Chie Iwakoshi, et al.
Journal of Pharmacological Sciences|April 23, 2011
Selective M3 muscarinic receptor antagonist inhibits small-cell lung carcinoma growth in a mouse orthotopic xenograft modelNozomi Ami, Kazumi Koga, Hiroshi Fushiki, et al.
Chemical & Pharmaceutical Bulletin|April 2, 2005
Discovery of 2-aminothiazole-4-carboxamides, a novel class of muscarinic M(3) selective antagonists, through solution-phase parallel synthesisYufu Sagara, Morihiro Mitsuya, Minaho Uchiyama, et al.
Bioorganic & Medicinal Chemistry Letters|June 12, 2003
Muscarinic M(3) receptor antagonists with (2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxyphenylacetamide Structures. Part 2Yoshio Ogino, Norikazu Ohtake, Kensuke Kobayashi, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 6, 2018
TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent ModelsHiroaki Hayashi, Ryusuke Kaneko, Shunsuke Demizu, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 27, 2012
[Two cases of interstitial pneumonia caused by cetuximab plus mFOLFOX6 therapy in metastatic colorectal cancer patients]Masanobu Shioiri, Makoto Hasegawa, Hiroaki Tanaka, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|March 8, 2005
Pituitary abscess in a patient with painless thyroiditisAkira Matsuno, Yoshio Ogino, Haruko Katayama, et al.
Expert Opinion on Therapeutic Patents|September 12, 2009
Modulation of neuropeptide Y receptors for the treatment of obesityNagaaki Sato, Yoshio Ogino, Satoshi Mashiko, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 15, 2011
[Trigger point therapy for myofascial pain in cancer patients (first report)-analysis results of special use-results surveillance by Neovitacain® injection-]Asami Yamaguchi, Yoshio Ogino, Chie Iwakoshi, et al.
Case Reports in Obstetrics and Gynecology|September 4, 2014
An Unusual Case of Fulminant Type 1 Diabetes during the Second Trimester of PregnancyTomohiro Okuda, Sadao Yamashita, Yoshio Ogino, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 17, 2012
[Trigger point therapy for myofascial pain in cancer patients (second report) analysis results of special use-results surveillance by neovitacain® injection]Asami Yamaguchi, Yoshio Ogino, Chie Iwakoshi, et al.
Journal of Pharmacological Sciences|April 23, 2011
Selective M3 muscarinic receptor antagonist inhibits small-cell lung carcinoma growth in a mouse orthotopic xenograft modelNozomi Ami, Kazumi Koga, Hiroshi Fushiki, et al.
Chemical & Pharmaceutical Bulletin|April 2, 2005
Discovery of 2-aminothiazole-4-carboxamides, a novel class of muscarinic M(3) selective antagonists, through solution-phase parallel synthesisYufu Sagara, Morihiro Mitsuya, Minaho Uchiyama, et al.
Bioorganic & Medicinal Chemistry Letters|June 12, 2003
Muscarinic M(3) receptor antagonists with (2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxyphenylacetamide Structures. Part 2Yoshio Ogino, Norikazu Ohtake, Kensuke Kobayashi, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 6, 2018
TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent ModelsHiroaki Hayashi, Ryusuke Kaneko, Shunsuke Demizu, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 27, 2012
[Two cases of interstitial pneumonia caused by cetuximab plus mFOLFOX6 therapy in metastatic colorectal cancer patients]Masanobu Shioiri, Makoto Hasegawa, Hiroaki Tanaka, et al.
Pageof 2